MEDP
Medpace Holdings, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$657.94
−0.84%Year over year
Reported trailing growth
- Revenue
- +20.4%
- EBITDA
- +19.3%
- EBIT
- +19.7%
- EPS
- +25.2%
- Free cash flow
- -5.1%
- Operating cash flow
- +1.7%
Forward estimates
Based on analyst estimates
- Revenue
- +4.2%
- EBITDA
- +3.7%
- EPS
- +5.0%
Three-year CAGR
- Revenue
- +20.1%
- EBITDA
- +22.8%
- EBIT
- +24.3%
- Net income
- +22.5%
- EPS
- +27.4%
- Free cash flow
- +24.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026